SCHEMBL23366154

SCHEMBL23366154

CNC1Cc2cc(Nc3ncc(F)c(Nc4ccccc4)n3)ccc2O1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 9/20 0.57
AURKA O14965 7/20 0.57
GSK3A P49840 2/20 0.57
GSK3B P49841 2/20 0.57
JAK2 O60674 2/20 0.57
AURKB Q96GD4 2/20 0.57
KDR P35968 2/20 0.57
ITK Q08881 2/20 0.57
PLK4 O00444 1/20 0.57
PDPK1 O15530 1/20 0.57
PRKD3 O94806 1/20 0.57
MAP4K4 O95819 1/20 0.57
NTRK1 P04629 1/20 0.57
INSR P06213 1/20 0.57
LCK P06239 1/20 0.57
FYN P06241 1/20 0.57
CDK1 P06493 1/20 0.57
FES P07332 1/20 0.57
CSF1R P07333 1/20 0.57
LYN P07948 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21282231 0.89 GSK3A (0.53) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL8999857 0.85 GSK3A (0.53) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL8999867 0.83 GSK3A (0.53) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL12554362 0.82 GSK3A (0.51) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL18594603 0.79 SYK (0.62) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL18653461 0.78 SYK (0.61) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL657064 0.76 AURKA (0.48) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL656585 0.76 SYK (0.52) SYKAURKAGSK3AGSK3BJAK2
SCHEMBL656122 0.76 SYK (0.47) SYKAURKAGSK3AGSK3BITK
SCHEMBL655338 0.76 AURKA (1.00) SYKAURKAGSK3AGSK3BJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A SYK 54/4885AURKA 997/4885GSK3A 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.